Curevac Vaccine Efficacy. The final estimate announced Wednesday evening is little changed from the 47 interim figure disclosed by CureVac two. Its the first late-stage study to flop with CureVacs vaccine showing 47 effectiveness.
CureVac said its COVID-19 vaccine was 48 effective in the final analysis of its pivotal mass trial only marginally better than the 47 reported after an initial read-out two weeks ago. However CureVac initially hoped to win European approval despite the lower efficacy. Overall the CureVac vaccine had an efficacy of just 48 percent against Covid-19.
That level is well below the efficacy achieved by other authorized COVID-19 vaccines.
CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its COVID-19 vaccine was 47 effective well short of the high bar set by. CureVac has released few details on the trial so far as it plans to release a fuller analysis during a company call Thursday. CVAC a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid mRNA today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine. However CureVac initially hoped to win European approval despite the lower efficacy.
